DSIP

DSIP (delta sleep-inducing peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from the cerebral venous blood of sleeping rabbits by Schoenenberger and Monnier in 1977, subsequently investigated for roles in sleep regulation, stress response modulation, and neuroendocrine activity across multiple neuropeptide systems. DSIP is proposed to act through modulation of GABAergic and serotonergic neurotransmission and to influence the release of multiple pituitary hormones including LH, GH, and ACTH, though no definitive receptor has been identified and its endogenous physiological role in mammalian sleep architecture remains incompletely understood. Foundational rodent studies demonstrated sleep-promoting effects following central or peripheral administration, and early small human EEG studies reported possible effects on sleep architecture; results have been inconsistent across studies, independent replication has been poor, and sleep-inducing activity in humans has not been established by any controlled clinical trial. DSIP has no FDA approval and no approved therapeutic indication in any jurisdiction; it is a research compound with an unconfirmed receptor target, an unclear mechanism of action, and an inconsistent human evidence base, and commercial availability through research peptide suppliers should not be interpreted as evidence of established clinical utility. DSIP dosage: No human clinical trial has established a reference dosing protocol for synthetic DSIP. Early human studies from the 1970s–80s used intravenous infusion at doses in the nanogram-to-microgram per kilogram range; these studies are dated and not replicated by modern clinical research standards. Research interest in DSIP has explored subcutaneous injection in research contexts. DSIP is a research compound with no approved human dosing guidelines for any indication.